Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAHX long-term extension study of baricitinib in pediatric juvenile idiopathic arthritis
MOH_2019-09-05_002414Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of baricitinib in juvenile idiopathic arthritis (JIA) and systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Eli Lilly and Company. Started Jul 2019; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on MOH_2019-09-05_002414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-05_002414.